howdy dy, it appears to me with the wording of the immutep/fda release and yesterday's
follow up that immutep are endeavouring to targetise their trial design as against
a more general exercise....
Ann: Immutep to present Phase IIb breast cancer data at ESMO 2022, page-12
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
35.0¢ |
Change
0.010(2.94%) |
Mkt cap ! $501.1M | |||
| Open | High | Low | Value | Volume |
| 34.0¢ | 35.5¢ | 34.0¢ | $569.3K | 1.637M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 18 | 199417 | 35.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.5¢ | 378267 | 41 |
View Market Depth
| Last trade - 13.05pm 16/08/2024 (20 minute delay) ? |
| IMM (ASX) Chart |